Active, not recruitingNCT05970913Updated Mar 23, 2026

PET-CT Predicting Lymph Nodes Metastasis

An observational study in Non Small Cell Lung Cancer, Lymph Node Metastasis and Positron Emission Tomography, sponsored by Fudan University. Active, not recruiting at 1 site in China. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-23.

Sponsored by Fudan University · Observational

From the registry’s dates

Primary completion was expected by Mar 2026, 6 months ago, but the record still lists the study as active, not recruiting.

Study type: Observational
Model: Cohort
Time perspective: Prospective
Enrollment: 280
Ages: 20 Years to 80 Years
Sex: All

Study summary

This study is a single-center prospective clinical study that aims to evaluate the predictive value of preoperative 18F-FDG-PET-CT and 18F-FAPI-PET/CT for lymph node metastasis in patients with non-small cell lung cancer. The final pathological results were used to assess the predictive value of PET-CT for lymph node metastasis.

Conditions studied

Non Small Cell Lung Cancer
Lymph Node Metastasis
Positron Emission Tomography

Browse trials for

In context

Carcinoma, Non-Small-Cell Lung

6,488 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,632 are open to participants now.

This study's planned enrollment of 280 is above the median of 161 across 949 observational studies indexed under Carcinoma, Non-Small-Cell Lung.

Browse Carcinoma, Non-Small-Cell Lung studies →

Lead sponsor

Fudan University is the lead sponsor of 1,270 studies on the registry; 623 are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 20 Years to 80 Years
Sexes eligible: All
Accepts healthy volunteers: No
Sampling method: Probability sample

Study population

Patients had non small cell lung cancer who received pathological examination of lymph nodes

Inclusion criteria

Solitary tumor, or multiple tumors with only ground-glass nodules (GGNs) apart from the primary lesion.
Diameter of the primary lesion ≤5cm, with a CTR between 0.5 and 1.
Pathological confirmation of non-small cell lung cancer (NSCLC) either before or during surgery.
No prior radiotherapy or chemotherapy for initial treatment.
No history of malignant tumors.

Exclusion criteria

Exclusion Criteria:

Locally advanced or distant metastasis.
Pleural dissemination observed during surgery.
History of malignant tumors.
Received neoadjuvant therapy.
Histopathological examination reveals lung malignancies other than non-small cell lung cancer (NSCLC).

Study design

Observational model: Cohort
Time perspective: Prospective
Enrollment: 280 participants (estimated)
Patient registry: No

What researchers measure

Primary outcomes

Predictive value of 18F-FDG-PET/CT and 18F-FAPI-PET/CT for lymph node metastasis
Time frame: from enrollment to 1 month after surgery

Study locations

1 site

Shanghai Cancer Center
Shanghai, China

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT05970913
Lead sponsor: Fudan University
Responsible party: Haiquan Chen (Chief of the MDT board of thoracic cancer, Fudan University) — Principal investigator
First posted: Aug 1, 2023
Start date: Nov 1, 2023
Primary completion: Mar 28, 2026 (estimated)
Completion: Mar 28, 2026 (estimated)
Last update: Mar 23, 2026

Oversight

Data monitoring committee: Yes
FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Carcinoma, Non-Small-Cell Lung→

Other studies from this sponsor

Fudan University

Start the discussion